Shared on08 Sep 25
Fair value Decreased 1.41%

Exelixis’ consensus price target saw a marginal decrease to $44.06 as enthusiasm for positive Phase 3 colorectal cancer trial results and potential new revenue from zanzalintinib was offset by revenue model reductions from the discontinuation of head and neck cancer development and ongoing concerns about long-term growth beyond the Cabometyx 2031 patent expiry. Analyst Commentary Bullish analysts raised price targets due to positive topline results from the STELLAR-303 Phase 3 trial, where zanzalintinib in combination with atezolizumab showed a statistically significant improvement in overall survival in metastatic colorectal cancer, paving the way for potential regulatory approval.

Shared on29 Jul 25
Fair value Increased 9.82%

Exelixis’ consensus price target has risen to $46.05, primarily driven by positive Phase 3 STELLAR-303 results for zanzalintinib, which boost expectations for regulatory approval and over $1B peak sales potential, while some analysts remain cautious on valuation and Cabometyx’s long-term outlook. Analyst Commentary Bullish analysts cite positive topline results from the STELLAR-303 Phase 3 trial, where zanzalintinib (Zanza) in combination with atezolizumab demonstrated statistically significant improvement in overall survival versus comparator regimens in non-microsatellite instability-high metastatic colorectal cancer.